FDA approves Shield's innovative iron-replenishing drug, Feraccru, to treat adult iron deficiency patients

Iron deficiency anemia means that both the patient's hemoglobin and serum ferritin are below normalWhen hemoglobin levels are normal and serum ferrite and/or transferritin saturation is below normal, anemia-free iron deficiency occursRecently, Therapeutic Shields announced thatFDA(http://approve the listing of its innovative iron-
drug(http://Feraccru for the treatment of adult iron deficiencyFeraccru's u.Smerchandise name will be AccruferAbout Accrufer
Accrufer's active ingredient is ferric maltol, a new, stable compound with non-iron saltsAccrufer has different absorption mechanisms, which contain iron that can be absorbed by intestinal cells and absorb only the amount of iron neededAccrufer is an ideal alternative therapy for patients who are intolerant of iron-salt-based tonic drugs 　　Previously, Accrufer has been approved in the European Union for the treatment of iron deficiency, and in Switzerland approved for the treatment of IBD-related iron deficiency anemia 　　In the aegis-H2H clinical trial (http:// , Accrufer met the non-performance standard compared to intravenous iron supplementtherapy 　　In other words, patients with iron deficiency anemia may not need intravenous iron supplementation therapy, and Accrufer is expected to change the treatment pattern for these patients